Aragen Integrated Drug Discovery (AIDD)

Aragen Integrated Drug Discovery (AIDD) offers innovative drug discovery solutions to our partners in their search for new drug candidates. At AIDD, we work in lockstep with our partners to deliver on their drug development strategy utilizing our specialized, well-trained teams.

Vision: To be the world’s leading partner in IDD, driving the accelerated discovery and development of innovative therapies that enhance patients’ lives

Why Aragen?

• We offer a comprehensive, end-to-end solution for drug discovery and development.
• Experienced drug hunters
• Expertise across therapeutic areas, target classes, and modalities
• Scientific excellence
• Seamless communication – work as an extension of your drug discovery team
• Operational excellence
• Efficiency in drug discovery/development – colocalization and coordination of activities
• Workflows with stringent timelines & budget
• Track Record

In vitro /In vivo Biology

• Protein and cell line generation
• Screening Platforms – HTS
• Electrophysiology
• Disease models – Oncology, Pain, Inflammation, Fibrosis etc.
• Histopathology & Clinical pathology

Discovery Chemistry

• Small scale synthesis to Tox material
• Various Technology platforms:
  • Largest SFC capabilities
  • Catalyst Screening Set-up
  • Parallel chemistry & Library synthesis
  • Peptides
  • Photo-redox/flow chemistry

DMPK

• Physicochemical studies
• ADME, PK & PK-PD

Computational Chemistry

• ML/AI models
• FBDD, SBDD and Virtual Screening
• Cheminformatics

Formulations

• Physical form profiling and selection
• PK/Tox formulation development
• Enabled formulation development

Safety Assessment Studies (GLP Tox)

• Exploratory tox study
• IND enabling safety assessment package
• NDA enabling study-Long term chronic, DART, Carcinogenicity, Tg.rasH2

Discovery Process Chemistry

• Route Scouting & Development support for Pre-clinical/Clinical Candidates
• PSM & QbD
• Salt screening & Polymorphs
• CMC support

With co-located cross functional teams of synthetic chemistry, in-vitro biology, in-vitro & in-vivo pharmacology, ADME, protein production, computational chemistry, process chemistry, formulations and safety assessment studies, we are best suited to move your candidate towards IND selection.

Our team has a track record of working in a broad range of programs in the small molecule and protein degrader modalities. These programs are aimed at discovering drug candidates that belong to various target classes such as GPCRs, kinases, transcription factors. They cover multiple therapeutic areas such as Oncology, Neurosciences, Cardiovascular, and are in various stages along the discovery pipeline.

Therapeutic Area	Target Class	Molecular Class	HIT ID	Lead Optimization	Preclinical Candidate	IND Enabling Studies
Fibrosis	GPCR	Small Molecule
Oncology	Kinase	Protein Degrader
Oncology	Tumor suppressor protein	Molecular Glue
Oncology	Transcription Factor	Small Molecule
Neurodegenerative Disease	Hydroxylase	Small Molecule
Oncology	mRNA modulator	Small Molecule
Neuroinflammation	Metabolic enzymes	Small Molecule
Neurosciences	Transferase	Small Molecule
Oncology	ATPase	Small Molecule
Oncology	Transferase	Small molecule & Protein degrader
Neurosciences	Transcription Factor	Small Molecule